|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM213716909 |
| 003 |
DE-627 |
| 005 |
20231224022140.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2012 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2011.10.003
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0712.xml
|
| 035 |
|
|
|a (DE-627)NLM213716909
|
| 035 |
|
|
|a (NLM)22154868
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Dueckers, Gregor
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis
|
| 264 |
|
1 |
|c 2012
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 11.04.2012
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2011 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and adolescents. Immunomodulatory drugs are used frequently in its treatment. Using the nominal group technique (NGT) and Delphi method, we created a multidisciplinary, evidence- and consensus-based treatment guideline for JIA based on a systematic literature analysis and three consensus conferences. Conferences were headed by a professional moderator and were attended by representatives who had been nominated by their scientific societies or organizations. 15 statements regarding drug therapy, symptomatic and surgical management were generated. It is recommended that initially JIA is treated with NSAID followed by local glucocorticoids and/or methotrexate if unresponsive. Complementing literature evidence with long-standing experience of caregivers allows creating guidelines that may potentially improve the quality of care for children and adolescents with JIA
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Anti-Inflammatory Agents, Non-Steroidal
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
| 650 |
|
7 |
|a Glucocorticoids
|2 NLM
|
| 650 |
|
7 |
|a Methotrexate
|2 NLM
|
| 650 |
|
7 |
|a YL5FZ2Y5U1
|2 NLM
|
| 700 |
1 |
|
|a Guellac, Nihal
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Arbogast, Martin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dannecker, Guenther
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Foeldvari, Ivan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Frosch, Michael
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ganser, Gerd
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Heiligenhaus, Arnd
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Horneff, Gerd
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Illhardt, Arnold
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kopp, Ina
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Krauspe, Ruediger
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Markus, Barbara
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Michels, Hartmut
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Schneider, Matthias
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Singendonk, Wolfram
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sitter, Helmut
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Spamer, Marianne
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wagner, Norbert
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Niehues, Tim
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 142(2012), 2 vom: 07. Feb., Seite 176-93
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:142
|g year:2012
|g number:2
|g day:07
|g month:02
|g pages:176-93
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2011.10.003
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 142
|j 2012
|e 2
|b 07
|c 02
|h 176-93
|